Pharmaceutical

Enzon and Viskase Announce Amendment to Merger Agreement

Enzon and Viskase stockholders will respectively own 45% and 55% of the combined companyCRANFORD, N.J. and LOMBARD, Ill., Oct. 24,…

2 months ago

StimCell Energetics Inc. Successfully Uplists to OTCQB Market

VANCOUVER, BC / ACCESS Newswire / October 24, 2025 / StimCell Energetics Inc. (OTCQB:STME) ("StimCell" or the "Company"), a biotech…

2 months ago

ASCP Introduces Age-Friendly Pharmacy (AFP) Recognition

ALEXANDRIA, VA / ACCESS Newswire / October 24, 2025 / ASCP has introduced a new Age-Friendly Pharmacy (AFP) recognition, designed…

2 months ago

Dental Materials and Implant Systems in Istanbul: What Patients Should Know (2025)

ISTANBUL, TURKEY / ACCESS Newswire / October 24, 2025 / Istanbul has rapidly become a global destination for dental implant…

2 months ago

HCA Healthcare Reports Third Quarter 2025 Results

Raises 2025 GuidanceNASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the third quarter ended…

2 months ago

Medical Care Technologies Inc. (OTC PINK:MDCE) Approved as Official Apple Developer

Company advances digital technology initiatives with approval to publish applications on Apple's App Store MESA, ARIZONA / ACCESS Newswire /…

2 months ago

Interactive Strength Inc. (NASDAQ: TRNR) to Release Third-Quarter Results on Friday, November 14, 2025

AUSTIN, TEXAS / ACCESS Newswire / October 24, 2025 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or the "Company"), maker of…

2 months ago

MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication

Advancing toward Phase 2a clinical evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast…

2 months ago

First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine

First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine…

2 months ago

Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference

FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in…

2 months ago